ESMO 2023 Lung Cancer Highlights from Community Oncology
In discussion with Dr. Alexander Spira covering the ESMO 2023 Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Spira
August 24, 2024
Key Points
PAPILLON – Amivantamab Plus Chemo in Advanced NSCLC with EGFR Exon 20 Insertions
MARIPOSA – Amivantamab Plus Lazertinib Versus Osimertinib as First-line Treatment in EGFR-mutated Advanced NSCLC
MARIPOSA-2 – Amivantamab Plus Chemo (with or without Lazertinib) vs Chemo in EGFR-mutated Advanced NSCLC After Progression on Osimertinib
LIBRETTO-431 – First-line Selpercatinib or Chemo and Pembrolizumab in RET Fusion-Positive Advanced NSCLC
Tags:
Related Posts
ConferencesWCLC2025ArticlesSeptember 18, 2025
WCLC 2025 Highlights: FLAURA2, HARMONi, ALCHEMIST with Dr. Balazs Halmos
ConferencesASCO2025July 31, 2025